Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in New York: - Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- The New York Hospital Medical Center of Queens — Flushing, New York
- Glens Falls Hospital — Glens Falls, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of CNY at Camillus — Camillus, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
- Glens Falls Hospital — Glens Falls, New York
Phase 3 Recruiting Network
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spr…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04510597
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- University of Rochester — Rochester, New York
- Phelps Memorial Hospital Center — Sleepy Hollow, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Memorial Sloan Kettering Commack — Commack, New York
- The New York Hospital Medical Center of Queens — Flushing, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
Phase 3 Recruiting Industry
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carc…
Sponsor: Arcus Biosciences, Inc.
NCT ID: NCT07011719
Sites in New York: - University of Rochester Medical Center — Rochester, New York
Phase 3 Recruiting Industry
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Sponsor: Xynomic Pharmaceuticals, Inc.
NCT ID: NCT03592472
Sites in New York: - Northwell Health/Monter Cancer Center — Lake Success, New York
- Mainstreet Physicans Care — Rochester, New York
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…
Sponsor: NRG Oncology
NCT ID: NCT05327686
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Glens Falls Hospital — Glens Falls, New York
- Northwell Health Cancer Institute at Huntington — Greenlawn, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in New York: - Albany Medical Center — Albany, New York
- Roswell Park Cancer Institute — Buffalo, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- Mount Sinai Hospital — New York, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other …
Sponsor: Pfizer
NCT ID: NCT07227415
Sites in New York: - New York Oncology Hematology, P.C. — Albany, New York
- New York Oncology Hematology - Clifton Park Cancer Center — Clifton Park, New York
Phase 1, Phase 2 Recruiting NIH
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first starte…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05896839
Sites in New York: - NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in New York: - NYU Langone Health Perlmutter Cancer Center — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Columbia University - The Trustees of Columbia University in the City of New York — New York, New York
- Montefiore Medical Center — New York, New York
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester — Rochester, New York
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05985161
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) — Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All protocol activites) — New York, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) — Rockville Centre, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07293351
Sites in New York: - Local Institution - 0096 — Hauppauge, New York
Phase 2 Recruiting NIH
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby t…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04981509
Sites in New York: - NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage.…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06413680
Sites in New York: - Northwell Health — Lake Success, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New York: - Local Institution - 0006 — New York, New York
- Local Institution - 0002 — New York, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in New York: - NYU Langone Health — New York, New York
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether the study drug, enfortumab vedotin, is an effective and safe treatment for people who have urothelial carcinoma of the upper urinary tract. Study participants will be people who are not elig…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05868265
Sites in New York: - Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities) — Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- University of Rochester Medical Center (Data Collection Only) — Rochester, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) — Uniondale, New York
Phase 1, Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether the combination of abemaciclib and cabozantinib is a safe and effective treatment for people with metastatic clear cell renal cell carcinoma (ccRCC) and translocation-associated rena…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06835972
Sites in New York: - Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06699602
Sites in New York: - Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York
Phase 1, Phase 2 Recruiting Industry
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experi…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07049926
Sites in New York: - Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026) — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center ( Site 5016) — New York, New York
- Memorial Sloan Kettering Cancer Center ( Site 5002) — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …
Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
Phase 2 Recruiting Academic/Other
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The pr…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05135975
Sites in New York: - Children's Hospital at Montefiore — The Bronx, New York